Research Scotland logo
View Item 
  •   Research Scotland Home
  • Biomathematics and Statistics Scotland (BioSS)
  • Journals
  • View Item
  •   Research Scotland Home
  • Biomathematics and Statistics Scotland (BioSS)
  • Journals
  • View Item
  •   Research Scotland Home
  • Biomathematics and Statistics Scotland (BioSS)
  • Journals
  • View Item
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.

Duration of protection and humoral immunity induced by an adenovirus- vectored foot-and-mouth disease virus serotype A24 subunit vaccine in Holstein steers

Thumbnail
Date
05/09/2019
Author
Sitt, T.
Kenney, M.
Barrera, J.
Pandya, M.
Eckstrom, K.
Warner, M.
Pacheco, J.M.
LaRocco, M.
Palarea Albaladejo, J.
Brake, D.
Rieder, E.
Arzt, J.
Barlow, J.W.
Golde, W.T.
Publisher
Elsevier
Version
2019-02-19
2019-02-19
Metadata
Show full item record
Abstract
The importance of an efficacious, long acting foot-and-mouth disease (FMD) vaccine is critical to control FMD. The human replication deficient adenovirus 5 (Ad5) empty capsid FMD virus (FMDV) platform (AdtFMD), is a promising new vaccine technology. Herein we describe three studies assessing the proportion of animals protected from clinical vesicular disease (foot lesions) following live-FMDV challenge by intradermolingual inoculation at 6 or 9 months following a single vaccination, and the potential effect of vaccination route (transdermal, intramuscular, subcutaneous) on clinical outcome. Results demonstrate that a single dose AdtA24 vaccination in cattle induced protection against clinical FMD at 6 months (100% transdermal, 80% intramuscular, and 60% subcutaneous) that waned by 9 months post-vaccination (33% transdermal and 20% intramuscular). Post-vaccination serum from immunized cattle (all studies) generally contained FMDV specific neutralizing antibodies by day 14. Overall, when specific Ig isotype responses were assessed, the number of IgG1 anti-FMDV antibody secreting cells detected in vaccinated steers compared to placebo-immunized controls was statistically significant (p=0.007). The decay in protective immunity over time may be a function of FMDV-specific antibody half-life due to loss of antibody secreting cells in circulation by four to five weeks post vaccination. These data reveal important performance characteristics of needle-free vaccination with a recombinant vectored subunit vaccine for FMDV.
DOI
https://doi.org/10.1016/j.vaccine.2019.08.017
Link
https://hdl.handle.net/20.500.12594/10102
Citation
Vaccine, 37, 6221-6231
Collections
  • Journals [121]
©Research Scotland Consortium
c/o RGBE 20a Inverleith Row
EH3 5LR
Edinburgh, Scotland, UK

Tel: 0131 248 2850
Email: info@ResearchScotland.ac.uk
Items in Research Scotland are protected by copyright with all rights reserved unless otherwise indicated.
  • Privacy & Cookies
  • Takedown Policy
  • Accessibility
  • Policies
  • Contact
Privacy & Cookies
Takedown Policy
Accessibility
Policies
Contact
 
Advanced Search

Browse

All of Research ScotlandPartners & CollectionsBy Issue DateAuthorsTitlesSubjectsPublishersThis CollectionBy Issue DateAuthorsTitlesSubjectsPublishers

My Account

LoginRegister
©Research Scotland Consortium
c/o RGBE 20a Inverleith Row
EH3 5LR
Edinburgh, Scotland, UK

Tel: 0131 248 2850
Email: info@ResearchScotland.ac.uk
Items in Research Scotland are protected by copyright with all rights reserved unless otherwise indicated.
  • Privacy & Cookies
  • Takedown Policy
  • Accessibility
  • Policies
  • Contact
Privacy & Cookies
Takedown Policy
Accessibility
Policies
Contact